Strides Pharma Science earnings calls.

Strides Pharma delivered a mixed Q3 FY26 with ₹236 crore EBITDACurrent reported value: ₹236 crore EBITDA. No comparable prior figure is available in the source record. (up 12% YoY, highest ever quarterly) and ₹128 crore operational PATCurrent reported value: ₹128 crore operational PAT. No comparable prior figure is available in the source record. (up 39Current reported value: 39. No comparable prior figure is available in the source record.%), driven by gross margin expansion to ~60% and strong XUS market performance at $64 million (up 20% YoY)Current $64 million (up 20% YoY). Reported change: +20% YoY.. However, overall revenue growth was muted at 3.6Current reported value: 3.6. No comparable prior figure is available in the source record.% due to institutional business weakness—excluding institutional, growth was 8.6-9%. US revenues remained flat at $70 millionCurrent reported value: $70 million. No comparable prior figure is available in the source record. impacted by delayed flu season, new competition in key products, and slower KOTA allocations. Management reiterated $400 million US target by FY28Current reported value: $400 million US target by FY28. No comparable prior figure is available in the source record. and plans to mirror US with XUS markets in two years. Balance sheet improved with Net Debt/EBITDA at 1.59xCurrent reported value: Net Debt/EBITDA at 1.59x. No comparable prior figure is available in the source record. (from 1.9x in FY25). ROCE improved to 15.8%. Key risks include US market concentration, seasonal volatility, and foreign exchange impact on rupee-denominated debt. Management appointed Peter Hardwick as North American CEO to drive US turnaround.